Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a… Read more
Market Cap & Net Worth: Lexeo Therapeutics, Inc. Common Stock (LXEO)
Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO) has a market capitalization of $465.66 Million ($465.66 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12773 globally and #5417 in its home market, demonstrating a -14.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lexeo Therapeutics, Inc. Common Stock's stock price $6.38 by its total outstanding shares 72987327 (72.99 Million).
Lexeo Therapeutics, Inc. Common Stock Market Cap History: 2023 to 2026
Lexeo Therapeutics, Inc. Common Stock's market capitalization history from 2023 to 2026. Data shows change from $979.49 Million to $465.66 Million (-20.51% CAGR).
Index Memberships
Lexeo Therapeutics, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #347 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1252 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.02% | #194 of 263 |
Weight: Lexeo Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lexeo Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lexeo Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LXEO by Market Capitalization
Companies near Lexeo Therapeutics, Inc. Common Stock in the global market cap rankings as of March 18, 2026.
Key companies related to Lexeo Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Lexeo Therapeutics, Inc. Common Stock Historical Marketcap From 2023 to 2026
Between 2023 and today, Lexeo Therapeutics, Inc. Common Stock's market cap moved from $979.49 Million to $ 465.66 Million, with a yearly change of -20.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $465.66 Million | -35.75% |
| 2025 | $724.76 Million | +50.91% |
| 2024 | $480.26 Million | -50.97% |
| 2023 | $979.49 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Lexeo Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $465.66 Million USD |
| MoneyControl | $465.66 Million USD |
| MarketWatch | $465.66 Million USD |
| marketcap.company | $465.66 Million USD |
| Reuters | $465.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.